The role of lebrikizumab in the treatment of atopic dermatitis in the adult population
Abstract
Although there are many atopic dermatitis (AD) treatments, finding a long-term medication with minimal side effects can be difficult. This review characterizes lebrikizumab as AD treatment in adults. A literature search was conducted to examine lebrikizumab's role in treating moderate to severe AD. In a phase III trial, 74% of adults with AD treated with lebrikizumab 250 mg every 4 weeks achieved an Investigator Global Assessment of 0/1, 79% achieved Eczema Area and Severity Index 75 and 79% experienced improvements in pruritus numeric rating scale scores relative to placebo. Common adverse effects in the ADvocate1 and ADvocate2 trials were conjunctivitis (7 and 8%, respectively), nasopharyngitis (4 and 5%, respectively) and headache (3 and 5%, respectively). Results from clinical trials suggest that lebrikizumab may be a viable alternative for AD management.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Topical corticosteroids and calcineurin inhibitors remain first-line treatments for atopic dermatitis, while topical JAK inhibitors provide targeted inhibition of cytokine signaling downstream of IL-4 and IL-13.
“Topical anti-inflammatory therapies, including corticosteroids and calcineurin inhibitors, remain first-line treatments, while topical JAK inhibitors provide targeted inhibition of cytokine signaling downstream of IL-4 and IL-13.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [13]
Treatment of atopic dermatitis targets epidermal barrier dysfunction and type 2 immune dysregulation.
“Treatment of atopic dermatitis targets the epidermal barrier dysfunction and type 2 immune dysregulation.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [13]
Emollients and ceramide-based moisturizers restore lipid composition, reduce transepidermal water loss, and limit allergen and microbial penetration.
“Management includes both barrier repair options and targeted immunomodulation, with emollients and ceramide-based moisturizers, which restore lipid composition, reduce transepidermal water loss, and limit allergen and microbial penetration.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [13]
In moderate-to-severe atopic dermatitis, systemic immunosuppressants such as cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil can be used, alongside oral JAK inhibitors that interfere with intracellular signaling pathways central to disease pathogenesis.
“In moderate-to-severe disease, systemic immunosuppressants can be used, such as cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil, alongside oral JAK inhibitors that interfere with intracellular signaling pathways central to disease pathogenesis.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [13]
Biologic therapies targeting type 2 inflammation, including dupilumab, lebrikizumab, and tralokinumab, have shown significant efficacy in moderate-to-severe atopic dermatitis by inhibiting IL-4 and IL-13 signaling.
“Biologic therapies targeting type 2 inflammation, including dupilumab, lebrikizumab, and tralokinumab, have shown significant efficacy in moderate-to-severe atopic dermatitis by inhibiting IL-4 and IL-13 signaling [11,12,13,14,15].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [13]
These atopic dermatitis therapies reduce inflammation and contribute to restoration of barrier function.
“These therapies reduce inflammation and contribute to the restoration of barrier function.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [13]
Cites
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266 · see citing works
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A. L., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,220 · see citing works
The burden of atopic dermatitis: summary of a report for the National Eczema Association.
Drucker, A. M., Wang, A. R., Li, W.-Q., Sevetson, E., Block, J. K., & Qureshi, A. A. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.07.012 · Cited by 720 · see citing works
Pathophysiology of atopic dermatitis: Clinical implications
Kim, J., Kim, B. E., & Leung, D. Y. M. (2019) · Allergy and Asthma Proceedings · doi:10.2500/aap.2019.40.4202 · Cited by 652 · see citing works
The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*
Laughter, M. R., Maymone, M. B. C., Mashayekhi, S., Arents, B. W. M., Karimkhani, C., Langan, S., Dellavalle, R. P., & Flohr, C. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19580 · Cited by 644 · see citing works
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623 · see citing works
Tsoi, L. C., Rodriguez, E., Degenhardt, F., Baurecht, H., Wehkamp, U., Volks, N., Szymczak, S., Swindell, W. R., Sarkar, M. K., Raja, K., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.12.018 · Cited by 469 · see citing works
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Simpson, E. L., Thyssen, J. P., Gooderham, M., Chan, G. L., Feeney, C., Biswas, P., Valdez, H., DiBonaventura, M., Nduaka, C. I., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.1406 · Cited by 413 · see citing works
Simpson, E. L., Lacour, J. ‐., Spelman, L., Galimberti, R., Eichenfield, L. F., Bissonnette, R., King, B. A., Thyssen, J. P., Silverberg, J. I., Bieber, T., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18898 · Cited by 396 · see citing works
Hanania, N. A., Noonan, M. J., Corren, J., Korenblat, P. E., Zheng, Y., Fischer, S. K., Cheu, M., Putnam, W. S., Murray, E., Scheerens, H., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206719 · Cited by 380 · see citing works
Guttman-Yassky, E., Blauvelt, A., Eichenfield, L. F., Paller, A. S., Armstrong, A. W., Drew, J., Gopalan, R., & Simpson, E. L. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0079 · Cited by 341 · see citing works
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Boguniewicz, M., Fonacier, L. S., Guttman‐Yassky, E., Ong, P. Y., Silverberg, J. I., & Farrar, J. R. (2017) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2017.10.039 · Cited by 308 · see citing works
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Simpson, E. L., Papp, K. A., Blauvelt, A., Chu, C., Hong, H., Katoh, N., Calimlim, B., Thyssen, J. P., Chiou, A. S., Bissonnette, R., et al. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.0029 · Cited by 215 · see citing works
Boguniewicz, M., Alexis, A. F., Beck, L. A., Block, J. K., Eichenfield, L. F., Fonacier, L. S., Guttman‐Yassky, E., Paller, A. S., Pariser, D. M., Silverberg, J. I., et al. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.08.005 · Cited by 190 · see citing works
Thaçi, D., Simpson, E. L., Deleuran, M. S., Kataoka, Y., Chen, Z., Gadkari, A. S., Eckert, L., Akinlade, B. K., Graham, N. M. H., Pirozzi, G., et al. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.02.002 · Cited by 188 · see citing works
Blauvelt, A., Thyssen, J. P., Guttman‐Yassky, E., Bieber, T. R. M., Serra‐Baldrich, E., Simpson, E. L., Rosmarin, D. M., Elmaraghy, H., Meskimen, E., Natalie, C. R., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad022 · Cited by 167 · see citing works
Simpson, E. L., Gooderham, M., Wollenberg, A., Weidinger, S., Armstrong, A. W., Soung, J., Ferrucci, S. M., Lima, R. G., Witte, M. M., Xu, W., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.5534 · Cited by 156 · see citing works
Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review
Fasseeh, A. N., Elezbawy, B., Korra, N., Tannira, M., Dalle, H., Aderian, S., Abaza, S., & Kaló, Z. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00819-6 · Cited by 138 · see citing works
Goujon, C., Viguier, M. A., Staumont-Sallé, D., Bernier, C., Guillet, G., Lahfa, M., le Bouëdec, M.-C. F., Cambazard, F., Bottigioli, D., Grande, S., et al. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.07.007 · Cited by 95 · see citing works
Phototherapy for atopic eczema
Musters, A. H., Mashayekhi, S., Harvey, J., Axon, E., Lax, S. J., Flohr, C., Drucker, A. M., Gerbens, L. A. A., Ferguson, J., Ibbotson, S. H., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013870.pub2 · Cited by 65 · see citing works
Adherence in Atopic Dermatitis
Patel, N., & Feldman, S. R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-64804-0_12 · Cited by 60 · see citing works
Tolerability of and Adherence to Topical Treatments in Atopic Dermatitis: A Narrative Review
Tier, H. L., Balogh, E. A., Bashyam, A. M., Fleischer, A. B., Spergel, J. M., Masicampo, E. J., Kammrath, L. K., Strowd, L. C., & Feldman, S. R. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00500-4 · Cited by 54 · see citing works
Sagransky, M. J., Yentzer, B. A., Williams, L. L., Clark, A. R., Taylor, S. L., & Feldman, S. R. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.368 · Cited by 48 · see citing works
Efficacy of biologics in atopic dermatitis
Wu, J., & Guttman-Yassky, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1722998 · Cited by 46 · see citing works
The Multidimensional Burden of Atopic Dermatitis Among Adults
Elsawi, R., Dainty, K. N., Begolka, W. S., Barta, K., Butler, L., Capozza, K., Eftekhari, S., Tullos, K. Z., Wu, W., & Drucker, A. M. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.1906 · Cited by 46 · see citing works
Phototherapy for atopic eczema
Musters, A. H., Mashayekhi, S., Flohr, C., Drucker, A. M., Gerbens, L., Ferguson, J., Ibbotson, S., Dawe, R. S., Garritsen, F., Brouwer, M., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013870 · Cited by 31 · see citing works
Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
Labib, A., Ju, T., & Yosipovitch, G. (2022) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s295672 · Cited by 31 · see citing works
Simpson, E. L., Wollenberg, A., Soong, W., Steffensen, L. A., Kurbasic, A., Schneider, S. K. R., Zoidis, J., & Silverberg, J. I. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.07.007 · Cited by 18 · see citing works
Dermatology for the internist: optimal diagnosis and management of atopic dermatitis
Narla, S., & Silverberg, J. I. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.2004322 · Cited by 17 · see citing works
Bashrahil, B., Alzahrani, Z., Samarkandy, S. J., Aman, A., & Jfri, A. H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1091271 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Silverberg, J. I., Bieber, T. R. M., Paller, A. S., Beck, L. A., Kamata, M., Puig, L., Wiseman, M., Ezzedine, K., Irvine, A. D., Foley, P. A., et al. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01357-7 · Cited by 27 · see citing works
Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026) · Dermatopathology · doi:10.3390/dermatopathology13020022 · Cited by 1 · see citing works
McKay, S., & Li, X.-M. (2026) · Current Allergy and Asthma Reports · doi:10.1007/s11882-026-01272-7 · Cited by 1 · see citing works
Yu, M., Li, J., Zhang, R., Cailin, B., & Cheng, G. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2603949
- Authors
- Prajapati, S., Fardos, M., Desai, A. D., & Feldman, S. R.
- Affiliations
- Wake Forest University Health Sciences (US)
- Rutgers New Jersey Medical School (US)
- Venue
- Immunotherapy
- Publisher
- Informa UK Limited
- Published
- 2023-07-04
- Volume
- 15
- Issue
- 13
- Pages
- 981-991
- ISSN
- 1750-743X (ISSN-L)
- 1750-7448
- OpenAlex
- W4383058627
- Cited by
- 4
- References
- 30
- Citations by year
- 2026: 2 · 2025: 2
- FWCI
- 0.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- lebrikizumab, atopic dermatitis, adult atopic dermatitis, IL-4 receptor alpha inhibition, moderate-to-severe atopic dermatitis, pruritus, Eczema Area and Severity Index, conjunctivitis, adverse effects, ADVOCATE trial
- MeSH terms
- Adult, Antibodies, Monoclonal, Dermatitis, Atopic, Humans, Severity of Illness Index, Treatment Outcome, Clinical Trials, Phase III as Topic, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
